(Q34165497)

31 July 2017

1 reference

title

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. (English)

1 reference

31 July 2017

Linda C Benavides

1

1 reference

31 July 2017

Alan K Sears

2

1 reference

31 July 2017

Jeremy D Gates

3

1 reference

31 July 2017

Guy T Clifton

4

1 reference

31 July 2017

Kevin S Clive

5

1 reference

31 July 2017

Mark G Carmichael

6

1 reference

31 July 2017

Jarrod P Holmes

7

1 reference

31 July 2017

Elizabeth A Mittendorf

8

1 reference

31 July 2017

Sathibalan Ponniah

9

1 reference

31 July 2017

George E Peoples

10

1 reference

31 July 2017

publication date

1 February 2011

1 reference

Expert Review of Vaccines

31 July 2017

published in

1 reference

31 July 2017

volume

10

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

201-210

1 reference

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Peptide and dendritic cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Toll-like receptor ligands energize peptide vaccines through multiple paths

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Progress and controversies in developing cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Laboratory analysis of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Editorial: Measurement of delayed skin-test responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.167

21 January 2018

Identifiers

DOI

10.1586/ERV.10.167

1 reference

31 July 2017

1 reference